Anistreplase FDA Link

An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.

Also Known As:

APSAC; Anisoylated Plasminogen-Streptokinase Activator Complex; BRL-26921; Eminase; Iminase; BRL 26921; BRL26921

Pharmalogical Action Categories:

Fibrinolytic Agents

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Peptide Hydrolases: 23957
      - Serine Proteases: 3726
        Serine Endopeptidases: 11
        Plasminogen Activators: 5174
        Anistreplase: 253
      - Endopeptidases: 633
        Streptokinase: 3519
        Anistreplase: 253
        Serine Endopeptidases: 11
        Plasminogen Activators: 5174
        Anistreplase: 253
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Blood Coagulation Factors: 5376
      - Plasminogen Activators: 5174
        Streptokinase: 3519
        Anistreplase: 253

Anistreplase Products